Zacks Research Has Positive Outlook for Perrigo Q3 Earnings

Perrigo Company plc (NYSE:PRGO) – Investment analysts at Zacks Research boosted their Q3 2026 earnings estimates for Perrigo in a report issued on Wednesday, May 27th. Zacks Research analyst Team now expects that the company will post earnings of $0.64 per share for the quarter, up from their previous forecast of $0.55. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.14 per share. Zacks Research also issued estimates for Perrigo’s Q4 2026 earnings at $0.72 EPS, FY2026 earnings at $2.10 EPS, Q1 2027 earnings at $0.60 EPS, Q2 2027 earnings at $0.58 EPS, Q3 2027 earnings at $0.60 EPS and Q4 2027 earnings at $0.72 EPS.

Several other equities analysts have also issued reports on the stock. Canaccord Genuity Group dropped their target price on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Price Performance

PRGO stock opened at $11.16 on Thursday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -0.85, a PEG ratio of 1.26 and a beta of 0.52. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. Perrigo has a 12-month low of $9.23 and a 12-month high of $28.43. The company’s fifty day simple moving average is $10.92 and its 200 day simple moving average is $12.67.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The company had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Perrigo’s revenue for the quarter was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Friday, May 29th will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.4%. The ex-dividend date is Friday, May 29th. Perrigo’s dividend payout ratio is currently -8.85%.

Institutional Investors Weigh In On Perrigo

Institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its position in Perrigo by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock worth $244,634,000 after purchasing an additional 653,925 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after acquiring an additional 1,101,154 shares during the period. Fuller & Thaler Asset Management Inc. grew its position in shares of Perrigo by 291.9% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after acquiring an additional 5,828,076 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Perrigo by 2.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,695,238 shares of the company’s stock valued at $171,367,000 after acquiring an additional 181,828 shares during the period. Finally, State Street Corp grew its position in shares of Perrigo by 9.5% during the 2nd quarter. State Street Corp now owns 7,340,323 shares of the company’s stock valued at $196,134,000 after acquiring an additional 637,678 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.